Treatment of Obstructive Sleep Apnea With Personalized Surgery in Children With Down Syndrome (TOPS-DS)
Launched by OREGON HEALTH AND SCIENCE UNIVERSITY · Aug 18, 2022
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
The TOPS-DS trial is studying a new way to treat obstructive sleep apnea (OSA) in children with Down syndrome. OSA is a condition where a child's breathing is interrupted during sleep, and it can lead to problems like sleepiness during the day, trouble with learning, and heart issues. Children with Down syndrome are at a much higher risk for OSA compared to other kids. This trial aims to see if a personalized surgical approach, guided by special observations made during sleep, can be more effective than the typical first treatment, which is called adenotonsillectomy (removing the tonsils and adenoids).
To be eligible for this trial, children must be between 2 and 17 years old, have Down syndrome, and have moderate to severe OSA. Their caregivers must be able to provide consent and speak either English or Spanish. Participants will undergo tests to determine their specific needs and then receive a tailored surgical procedure to help improve their breathing during sleep. This approach hopes to provide better outcomes and reduce unnecessary surgeries in the future.
Gender
ALL
Eligibility criteria
- Requirements to participate in study:
- • Child has a diagnosis of Down syndrome (Trisomy 21). Child has a diagnosis of moderate to severe OSA diagnosed by PSG (oAHI ≥ 5). Child age is 2.00 to 17.99 years of age. Caregiver can provide signed and dated consent and is 18 years of age or older at the time of consent.
- • Caregiver can speak, read, and write in English or Spanish. Caregiver is primary caretaker of the child. Child is not expecting their own child. Child is eligible for surgical treatment
- Cannot participate in study if:
- • Child has history of previous tonsillectomy, tonsillotomy, or partial tonsillectomy.
- • Child has any contraindication to surgery (e.g. bleeding disorders). Child has significant cardiopulmonary comorbidity besides OSA requiring supplemental oxygen, subglottic or tracheal stenosis, tracheostomy dependence.
- • Caregiver is unwilling or unable to comply with study procedures. Child is or plans to have their own child.
About Oregon Health And Science University
Oregon Health and Science University (OHSU) is a leading academic medical center dedicated to advancing health through research, education, and patient care. As a prominent sponsor of clinical trials, OHSU leverages its extensive expertise in various medical fields to facilitate innovative research aimed at improving patient outcomes. The institution is committed to ethical standards and rigorous scientific methodologies, fostering collaborations that enhance the development of new therapies and interventions. With a focus on translating research discoveries into clinical practice, OHSU plays a pivotal role in shaping the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ann Arbor, Michigan, United States
Houston, Texas, United States
Portland, Oregon, United States
Cincinnati, Ohio, United States
Dallas, Texas, United States
Aurora, Colorado, United States
Norfolk, Virginia, United States
Patients applied
Trial Officials
Derek Lam, MD, MPH
Principal Investigator
Oregon Health and Science University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials